保健衛生学部　リハビリテーション学科
  1. Researcher List
  2. Naoki Yamamoto

Naoki Yamamoto

  (山本 直樹)

Profile Information

Affiliation
Professor (PhD), Department of Pharmaceutical Engineering, Faculty of Engineering, Sanyo-Onoda City University
Professor (PhD), University Startup Promotion Center, Innovation Promotion Division, Research Promotion Headquarters, Fujita Health University
Degree
医学博士(藤田保健衛生大学)
Contact information
naokiyrs.socu.ac.jp
Researcher number
00267957
J-GLOBAL ID
200901054071171303
researchmap Member ID
6000005815
External link

Research Interests

 16

Research Areas

 6

Research History

 14
More

Education

 1

Committee Memberships

 16
More

Awards

 14
More

Papers

 219
  • Hiroko Otake, Rie Tanaka, Fumihiko Ogata, Manju Misra, Kazutaka Kanai, Masanobu Tsubaki, Naoki Yamamoto, Naohito Kawasaki, Noriaki Nagai
    Pharmaceutics, Aug, 2026  
  • Koji Komatsu, Atsushi Toma, Yoichiro Masuda, Masanobu Iida, Kosuke Ichihara, Ai Iwauchi, Hoshiho Kubota, Yosuke Nakazawa, Naoki Yamamoto, Masayuki Shimoda, Tadashi Nakano
    Graefe's Archive for Clinical and Experimental Ophthalmology, Jun 11, 2026  
  • Hiroko Otake, Rie Tanaka, Fumihiko Ogata, Yosuke Nakazawa, Manju Misra, Kazutaka Kanai, Masanobu Tsubaki, Naoki Yamamoto, Naohito Kawasaki, Noriaki Nagai
    Pharmaceutics, Jun, 2026  
  • Yu Kato, Naoki Yamamoto, Yuichiro Uchida, Noriko Hiramatsu, Takato Ozeki, Yukari Minobe, Yukika Hasegawa, Sho Kawabe, Hikaru Yabuuchi, Seiji Yamada, Yuko Hata, Eiji Sugihara, Tetsuya Takimoto, Kuniaki Saito, Takeshi Takahara, Koichi Suda, Osamu Nagano, Hideyuki Saya
    Cells, Feb, 2026  
  • Kazuya Fujimoto, Hiroko Otake, Rie Tanaka, Fumihiko Ogata, Chika Fujii, Naoki Yamamoto, Naohito Kawasaki, Toshihiko Ishizaka, Takeshi Kotake, Noriaki Nagai
    Journal of pharmaceutical health care and sciences, 12(1) 23-23, Jan 24, 2026  
    BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for managing inflammatory disorders such as rheumatoid arthritis (RA); however, their long-term use is frequently associated with gastrointestinal (GI) complications, often leading to RA treatment discontinuation. To address this issue, we developed an oral formulation of troxipide (TRO), a pharmaceutical agent with gastroprotective properties, using nanosuspension technology to enhance its GI absorption and therapeutic efficacy. METHODS: The TRO nanosuspensions (TRO-NP@dis) were prepared by bead milling with methylcellulose (MC) as a stabilizing agent, yielding particles with an average diameter of 148 nm. An adjuvant-induced arthritis (AA) rat model, characterized by heightened susceptibility to NSAID-induced GI injury, was employed to assess pharmacokinetics and therapeutic efficacy. RESULTS: TRO-NP@dis showed improved dispersibility relative to conventional microparticle dispersions (TRO-MP@dis). Although the viscosities and zeta potentials of TRO-MP@dis and TRO-NP@dis were comparable, the solubility of TRO-NP@dis was markedly higher. Pharmacokinetic studies in rats revealed enhanced retention of TRO in the stomach, jejunum, and ileum following oral administration of TRO-NP@dis compared with TRO-MP@dis. Indomethacin (IND) administration (40 mg/kg) significantly increased the mucosal lesion area in AA rats compared to that in controls. However, the co-administration of TRO-NP@dis significantly reduced the lesion areas in the stomach, jejunum, and ileum compared to those in vehicle-treated AA rats, indicating notable protective effects. These findings suggested that TRO-NP@dis confers enhanced mucosal adhesion and retention, leading to improved therapeutic outcomes in patients with IND-induced GI injury. CONCLUSIONS: This nanosuspension-based delivery system represents a promising approach for mitigating NSAID-related GI complications in patients with RA by increasing local drug concentrations and reducing mucosal damage.
More

Misc.

 69
  • 久保田ちか, 門脇玲太, 浅井拓己, 大竹裕子, 中澤洋介, 山本直樹, 長井紀章
    日本医療薬学会年会講演要旨集(Web), 33rd, 2023  
  • 門脇玲太, 浅井拓己, 出口粧央里, 大竹裕子, 中澤洋介, 山本直樹, 長井紀章
    日本白内障学会総会・水晶体研究会プログラム・講演抄録集, 62nd-49th, 2023  
  • 山本直樹, 山本直樹, 平松範子, 佐々木洋, 近藤征史, 小島肇
    Journal of Toxicological Sciences, 46(Supplement), 2021  
  • 林 卓馬, 山本 直樹, 田島 香里, 長谷川 正樹, 谷口 巧, 藤田 順之, 石村 大輔
    日本整形外科学会雑誌, 94(8) S1859-S1859, Sep, 2020  
  • Tomohide Souma, Tomoyuki Minezawa, Hiroshi Yatsuya, Takuya Okamura, Kumiko Yamatsuta, Sayako Morikawa, Tomoya Horiguchi, Shingo Maeda, Yasuhiro Goto, Masamichi Hayashi, Sumito Isogai, Naoki Yamamoto, Masashi Kondo, Kazuyoshi Imaizumi
    Chest, 158(2) 797-807, Mar 4, 2020  
    BACKGROUND: Infectious complications after endobronchial ultrasound-guided transbronchial biopsy with a guide sheath (EBUS-GS-TBB) are serious in that they may delay or change scheduled subsequent therapy. The aim of this study was to identify risk factors for infection after EBUS-GS-TBB. RESEARCH QUESTION: What are the risk factors for infection after EBUS-GS-TBB? STUDY DESIGN AND METHODS: We retrospectively reviewed the medical records of 1,045 consecutive patients who had undergone EBUS-GS-TBB for peripheral lung lesions between January 2013 and December 2017 at Fujita Health University Hospital. We evaluated the following risk factors for infectious complications after EBUS-GS-TBB: relevant patient characteristics (age and comorbidities), lesion size, CT scan features of target lesion (intratumoral low-density areas [LDAs] and cavitation), stenosis of responsible bronchus observed by bronchoscopy, and laboratory data before EBUS-GS-TBB (WBC count and C-reactive protein concentration). RESULTS: Forty-seven of the study patients developed infectious complications (24 with pneumonia, 14 with intratumoral infection, three with lung abscess, three with pleuritis, and three with empyema), among whom the complication caused a delay in cancer treatment in 13 patients, cancellation of cancer treatment in seven patients, and death in three patients. Multivariate analysis showed that cavitation (P = .007), intratumoral LDAs (P < .001), and stenosis of responsible bronchus observed by bronchoscopy (P < .001) were significantly associated with infectious complications after EBUS-GS-TBB. Prophylactic antibiotics had been administered to 13 patients in the infection group. Propensity matched analysis could not show significant benefit of prophylactic antibiotics in preventing post-EBUS-GS-TBB infections. INTERPRETATION: Cavitation, LDAs for CT scan features of target lesions, and stenosis of responsible bronchus observed by bronchoscopy are risk factors of post-EBUS-GS-TBB infection. In the cohort, prophylactic antibiotics failed to prevent infectious complications.
More

Books and Other Publications

 10
  • 山本 直樹 (Role: Contributor, 第2章 動物実験代替法における評価モデル 、第3節 不死化ヒト角膜上皮細胞株を用いた眼刺激性試験代替法)
    株式会社 技術情報協会, Jun, 2018
  • 山本 直樹 (Role: Joint author, 細胞培養基盤技術)
    株式会社 じほう, Jun, 2013
  • 山本 直樹 (Role: Contributor, フルオレセイン漏出試験法（Fluorescein leakage test method; FL試験法）)
    株式会社 シーエムシー出版, Jun, 2013
  • 山本 直樹 (Role: Contributor, アトピー白内障 －その発症に関与する要因とメカニズム－)
    学際企画株式会社, Jun, 2011
  • 山本 直樹 (Role: Contributor, 子どもに多い目の病気 “感染予防の必要性の有無と指導の実際")
    健学社, Oct, 2008
More

Presentations

 51
More

Teaching Experience

 7
More

Professional Memberships

 8
More

Works

 1

Research Projects

 24
More

Industrial Property Rights

 4

Other

 3
  • 市販のリプログラミングベクターを用いて、ヒト末梢血単球由来iPS細胞を作製することに成功した。研究成果は、以下のジャーナルで報告している。Isogai S, Yamamoto N et al., Cell Reprogram 20(6), 347-355, 2018. Hiramatsu N, Yamamoto N et al., Med Mol Morphol 53(2), 63-72, 2020. ＊本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター（fuji-san@fujita-hu.ac.jp）まで
  • ヒト虹彩由来iPS細胞の作製に成功した。研究成果は、以下のジャーナルで報告している。Yamamoto N et al., Cells 10(4), 743, 2021. ＊本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター（fuji-san@fujita-hu.ac.jp）まで
  • 臓器・組織を迅速に固定できる固定液を発明。日本で特許を取得（特許3723204 難浸透性組織迅速固定液）。本特許の技術の一部を利用した商品（組織用迅速固定液 スーパーフィックス KY-500, クラボウ）が販売されている。他にも、本特許技術を用いた無ホルマリン固定液を開発中。 ＊本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター（fuji-san@fujita-hu.ac.jp）まで
To the list screen